focus -WSS

focus

author：comprehensive 2025-09-06 20:53:39 - browse：585

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： FDA rejects Alnylam's heart disease treatment over insufficient data

hotspot

focus

WSS

Merck to acquire Harpoon Therapeutics for $680 million

Chan Zuckerberg Biohub Chicago to focus on inflammation

Why Charlie Gard's case is so disturbing to Americans

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

A Q&A with the global head of Boehringer Ingelheim's innovation unit

explore

focus

knowledge

Sports medicine is finally prioritizing gender equality

Study suggests new cause of Down syndrome: cells linked to aging

Peter Hotez and the public health issue of online harassment

Hospital chaplains balance Covid safety with patients’ spiritual needs

Supreme Court strikes down use of affirmative action

Why Charlie Gard's case is so disturbing to Americans

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Guidelines to prevent youth baseball injuries need more muscle

Allen Institute goes after foundational questions, CEO Costa says

leisure time

Bill would stop addiction treatment from triggering child abuse inquiry

What to expect at HLTH 2023, the health care industry conference

Arena BioWorks launches in Cambridge to speed drug discovery

Was Amgen transparent enough on FDA's concern on cancer drug?

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Colorectal cancer study finds potential in overlooked immune cell

leisure time

hotspot

focus

entertainment